Optimized post-operative surveillance of permanent pacemakers by home monitoring: the OEDIPE trial

Aims The ŒDIPE trial examined the safety and efficacy of an abbreviated hospitalization after implantation or replacement of dual-chamber pacemakers (PM) using a telecardiology-based ambulatory surveillance programme. Methods and results Patients were randomly assigned to (i) an active group, discha...

Full description

Saved in:
Bibliographic Details
Published in:Europace (London, England) England), 2008-12, Vol.10 (12), p.1392-1399
Main Authors: Halimi, Franck, Clémenty, Jacques, Attuel, Patrick, Dessenne, Xavier, Amara, Walid
Format: Article
Language:English
Subjects:
Aged
Clinical Research
Female
France - epidemiology
Home Care Services - statistics & numerical data
Humans
Male
Pacemaker, Artificial
Postoperative Care - statistics & numerical data
Product Surveillance, Postmarketing - methods
Product Surveillance, Postmarketing - statistics & numerical data
Quality Assurance, Health Care - methods
Remote Consultation - methods
Remote Consultation - statistics & numerical data
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims The ŒDIPE trial examined the safety and efficacy of an abbreviated hospitalization after implantation or replacement of dual-chamber pacemakers (PM) using a telecardiology-based ambulatory surveillance programme. Methods and results Patients were randomly assigned to (i) an active group, discharged from the hospital 24 h after a first PM implant or 4-6 h after replacement, and followed for 4 weeks with Home-Monitoring (HM), or (ii) a control group followed for 4 weeks according to usual medical practices. The primary objective was to confirm that the proportion of patients who experienced one or more major adverse events (MAE) was not higher in the active than in the control group. The study included 379 patients. At least one treatment-related MAE was observed in 9.2% of patients (n = 17) assigned to the active group vs. 13.3% of patients (n = 26) in the control group (P = 0.21), a 4.1% absolute risk reduction (95% CI −2.2 to 10.4; P = 0.98). By study design, the mean hospitalization duration was 34% shorter in the active than in the control group (P < 0.001), and HM facilitated the early detection of technical issues and detectable clinical anomalies. Conclusion Early discharge with HM after PM implantation or replacement was safe and facilitated the monitoring of patients in the month following the procedure.
ISSN:1099-5129
1532-2092
DOI:10.1093/europace/eun250